Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $460.74M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.33M
Average 0.17M
Returns on capital
Assembly Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.0%
avg -62.2%
ROIC
-5.8%
avg -46.0%
ROA
-2.4%
avg -37.8%
Analysis
ROA is currently the strongest return metric at -2.4% versus its period average of -37.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jason A. Okazaki | Chief Executive Officer, President & Director | USD 1.25M | 50 | 195.53K | 1.23% |
William E. Delaney | Chief Scientific Officer | USD 829.37K | 54 | — | — |
Anuj Gaggar | Chief Medical Officer | USD 820.67K | 48 | 53.80K | 0.34% |
Nicole S. White | Chief Manufacturing Officer | USD 655.84K | 46 | 59.26K | 0.37% |
Thomas E. Rollins | Executive Officer | USD 472.55K | 70 | 3.75K | 0.02% |
Amy Figueroa | Investor Relations Consultant | — | — | — | — |
Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | — | — | — | — |
Jennifer A. Troia MHROD SHRM-SCP SPHR | Chief Human Resources Officer | — | — | — | — |
Katie Kitrinos | Senior Vice President of Preclinical Research & Development | — | — | — | — |
Jeanette Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | — | 39 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$252,334.57
Net Transaction Value
−$252,334.57
Net selling
Most Active
Bjorkquist Jeanette M
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 2, 26Nov 2, 2026 | Gaggar Anuj Direct | Sell | $50.3K$50,274.14 |
| Nov 2, 26Nov 2, 2026 | Gaggar Anuj Direct | Sell | $590.1$590.09 |
| Nov 2, 26Nov 2, 2026 | White Nicole S Direct | Sell | $50.3K$50,274.14 |
| Nov 2, 26Nov 2, 2026 | Okazaki Jason A Direct | Sell | $120.3K$120,254.02 |
| Nov 2, 26Nov 2, 2026 | Okazaki Jason A Direct | Sell | $1.4K$1,404.01 |
| Nov 2, 26Nov 2, 2026 | White Nicole S Direct | Sell | $590.1$590.09 |
| Nov 2, 26Nov 2, 2026 | Bjorkquist Jeanette M Direct | Sell | $183.1$183.13 |
| Nov 2, 26Nov 2, 2026 | Bjorkquist Jeanette M Direct | Sell | $14.1K$14,078.33 |
| Jun 17, 26Jun 17, 2026 | Bjorkquist Jeanette M Direct | Sell | $674.3$674.25 |
| Mar 30, 26Mar 30, 2026 | Bjorkquist Jeanette M Direct | Sell | $8.3K$8,314.86 |
1–10 of 13
Summary
Insiders reported 0 buys worth $0.00 and 13 sells worth $252,334.57 over the last 12 months. That adds up to net selling of $252,334.57. Bjorkquist Jeanette M was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +10.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +10.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Assembly Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ASMB's management, answered from reported figures.
Who manages ASMB?
Assembly Biosciences, Inc. (ASMB) lists 10 active executives. The top listed executive is Amy Figueroa, Investor Relations Consultant.
Are ASMB insiders buying or selling?
Recent insider activity shows net buying of $93.42M.
Continue the stock analysis
Jump to another research area for this company.